Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+ / HR+ early breast cancer (eBC).

D Lüftner; R Bartsch; U Breitenstein; M Balic; C Jackisch; V Müller; G Rinnerthaler; M Schmidt; M Schwitter; K Zaman; D Wrobel; D Guth; J Terhaag; M Zaiss; A Distelrath; A Lorenz; T Schinköthe; N Harbeck, 2022.

Oncol Res Treat 2022;45(suppl 1):19

Download